Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTITUMOR ACTIVITY OF PF-07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS

NCT06285097 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT06285097
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06285097 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETIC, PHARMACODYNAMIC, AND ANTITUMOR ACTIVITY OF PF-07820435 AS MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH ADVANCED SOLID TUMORS
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Terminated
Start date
February 8, 2024
Completion date
February 13, 2025
Enrollment
9 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal carcinoma, melanoma, neoplasms, non-small-cell lung cancer, ovarian carcinoma, renal cell carcinoma, squamous cell carcinoma of the head and neck, urothelial carcinoma